Literature DB >> 11846134

Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application.

L Corash1.   

Abstract

Mesh：

Year:  2001        PMID： 11846134     DOI： 10.1016/s1473-0502(01)00116-1

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN： 1473-0502            Impact factor:   1.764


× No keyword cloud information.
  3 in total

Review 1.  Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies.

Authors:  Kathryn E Webert; Christine M Cserti; Judy Hannon; Yulia Lin; Katerina Pavenski; Jacob M Pendergrast; Morris A Blajchman
Journal:  Transfus Med Rev       Date:  2008-01

Review 2.  Pathogen inactivation techniques.

Authors:  J P R Pelletier; S Transue; E L Snyder
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

3.  Pathogen-reduction methods: advantages and limits.

Authors:  H G Klein; B J Bryant
Journal:  ISBT Sci Ser       Date:  2009-02-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.